Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

As president of the Novartis Institutes for BioMedical Research, or NIBR, Bradner leads the company's drug research and discovery. But, speaking at the World Economic Forum in Davos, Switzerland ...

Sato, Vicki, Christoph Jaeker, and Pooja Mehta Solanki. "China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise." Harvard Business School ...

Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...

One year ago this week, Novartis biomedical research president Fiona Marshall called artificial intelligence a technology with “the potential to transform how we discover new drugs.” ...

Dr. Roubenoff is Head of Global Translational Medicine for Musculoskeletal Diseases at Novartis Institutes for Biomedical Research. He has done pioneering work on the interactions of nutrition, ...

Undaunted by the controversy over its $50 million deal to fund agricultural research at the University of California at Berkeley (UCB) a year ago, the Swiss company Novartis has recently announced ...